Fig. 5.
Overall survival for patients with de novo CD5+ DLBCL and with cyclin D1+ MCL.
De novo CD5+ DLBCL showed an initially more aggressive clinical course than MCL, but the survival curve crossed that of MCL 5 years after diagnosis and showed superior survival thereafter.